Markers of inflammatory status are associated with hearing threshold in older people: findings from the Hertfordshire ageing study

Verschuur, Carl; Dowell, Aphra; Syddall, Holly; Ntani, Georgia; Simmonds, Shirley; Baylis, D.; Gale, Catharine R.; Walsh, Bronagh; Cooper, Cyrus; Lord, Janet M.; Sayer, Avan Aihie

doi:10.1093/ageing/afr140

Cited by 92 publications

(71 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(2012). This group examined relationships between hearing thresholds and key serum biomarkers of low-grade inflammation (Vershcuur et al, 2012). They utilized findings from the British birth cohort study known as the Hertfordshire Ageing Study.…”

Section: Chronic Inflammation In Age-related Hearing Lossmentioning

confidence: 99%

Chronic inflammation – inflammaging – in the ageing cochlea: A novel target for future presbycusis therapy

Watson

Ding

Liu

et al. 2017

Ageing Research Reviews

149

View full text Add to dashboard Cite

Chronic, low-grade inflammation, or inflammaging, is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the nervous system. Over the past two decades, much effort has been done to understand the mechanisms of inflammaging in disease models such as type II diabetes, cardiovascular disease, Alzheimer’s disease, Parkinson’s disease, and others. However, despite being the most prevalent neurodegenerative disorder, the number one communication disorder, and one of the top three chronic medical conditions of our aged population; little research has been conducted on the potential role of inflammation in age-related hearing loss (ARHL). Recently, it has been suggested that there is an inflammatory presence in the cochlea, perhaps involving diffusion processes of the blood-brain barrier as it relates to the inner ear. Recent research has found correlations between hearing loss and markers such as C-reactive protein, IL-6, and TNF-α indicating inflammatory status in human case-cohort studies. However, there have been very few reports of in vivo research investigating the role of chronic inflammation’s in hearing loss in the aging cochlea. Future research directed at better understanding the mechanisms of inflammation in the cochlea as well as the natural changes acquired with aging may provide a better understanding of how this process can accelerate presbycusis. Animal model experimentation and pre-clinical studies designed to recognize and characterize cochlear inflammatory mechanisms may suggest novel treatment strategies for preventing or treating ARHL. In this review, we seek to summarize key research in chronic inflammation, discuss its implications for possible roles in ARHL, and finally suggest directions for future investigations.

show abstract

Section: Chronic Inflammation In Age-related Hearing Lossmentioning

confidence: 99%

Chronic inflammation – inflammaging – in the ageing cochlea: A novel target for future presbycusis therapy

Watson

Ding

Liu

et al. 2017

Ageing Research Reviews

149

View full text Add to dashboard Cite

show abstract

“…There have been non-significant cardiovascular and hearing results (Drettner et al 1975;Pratt et al 2009), however, as well as evidence for inflammatory disease rather than vascular disease underlying presbyacusis (Bainbridge et al 2010;Verschuur et al 2012). Inconsistent vascular findings may be due to evidence that associations between metrics of vascular health and hearing appear to be most consistent for low frequency hearing thresholds (Gates et al 1993;Pirodda et al 1999;Rosenhall and Sundh 2006;Helzner et al 2011).…”

Section: Introductionmentioning

confidence: 99%

White Matter Hyperintensities Predict Low Frequency Hearing in Older Adults

Eckert

Kuchinsky

Vaden

et al. 2013

JARO

View full text Add to dashboard Cite

Vascular disease has been proposed as a contributing factor for presbyacusis (age-related hearing loss). While this hypothesis is supported by pathological evidence of vascular decline in post-mortem human and animal studies, evidence in human subjects has been mixed with associations typically reported between a measure of vascular health and low frequency hearing in older women. Given the difficulty of characterizing the in vivo health of the cochlear artery in humans, an estimate of cerebral small vessel disease was used to test the prediction that age-related change in low frequency hearing and not high frequency hearing is related to a global decline in vascular health. We examined the extent to which these associations were specific to women and influenced by a history of high blood pressure in 72 older adults (mean age 67.12 years, SD08.79). Probability estimates of periventricular white matter hyperintensities (WMH) from T1-and fluid attenuated T2-weighted magnetic resonance images were significantly associated with a low frequency hearing metric across the sample, which were independent of age, but driven by women and people with a history of high blood pressure. These results support the premise that vascular declines are one mechanism underlying age-related changes in low frequency hearing.

show abstract

“…Other inflammatory biomarkers like white blood cell count, neutrophil count, IL-6 and CRP are associated with hearing loss in older people 19 . Over a 10 year period, older people with higher levels of CRP were two times more likely to develop hearing loss than normal 20 .…”

Section: Discussionmentioning

confidence: 99%

“…There is evidence from humans linking inflammatory states to age-related hearing loss by correlation of markers of mild systemic inflammatory states (raised IL-6 and CRP levels) with hearing loss (Verschuur C, et al . 2012 5 ). In other words, a reasonable hypothesis would be that low dose aspirin is actually protective against age-related hearing loss.…”

mentioning

confidence: 99%

Evaluation of hearing level in patients on long term aspirin therapy

Pokharel

Bhandary

2017

F1000Res

View full text Add to dashboard Cite

Introduction: Aspirin is a routinely prescribed drug, most notably for cardiovascular diseases, such as myocardial ischemia. This cross sectional, comparative study study aims to explore differences in hearing status between the cardiovascular disease patients on aspirin therapy and age matched healthy controls. Methods: The study population consisted of 182 patients with heart disease taking long term aspirin (i.e., for more than one year). The control population consisted of 221 age matched healthy controls who were not taking aspirin. Results: Not aspirin, but the age of the patient was found to be the important risk factor for hearing loss. Conclusions: When confounding factors like age of the patient, hypertension and diabetes were taken into account, aspirin in its antiplatelet dose was not found to be the cause of any audiological problems like tinnitus and hearing loss.

show abstract

Markers of inflammatory status are associated with hearing threshold in older people: findings from the Hertfordshire ageing study

Cited by 92 publications

References 21 publications

Chronic inflammation – inflammaging – in the ageing cochlea: A novel target for future presbycusis therapy

Chronic inflammation – inflammaging – in the ageing cochlea: A novel target for future presbycusis therapy

White Matter Hyperintensities Predict Low Frequency Hearing in Older Adults

Evaluation of hearing level in patients on long term aspirin therapy

Contact Info

Product

Resources

About